According to Zacks, “Eli Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly expects to launch 20 new products in a 10 year time-frame ranging from 2014 to 2023 and could launch at least two new indications/line extensions on an average every year. Products like Humalog, Trajenta, Cialis, Forteo, Strattera, Erbitux, and the animal health segment should drive growth while revenues from new products like Cyramza, Trulicity, Jardiance, Portrazza and Basaglar will pick up. However, Alimta will continue to be impacted by competition. Headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Estimates have been mostly stable ahead of the company’s Q3 earnings release. The company has a positive record of earnings surprises in recent quarters.”
Other equities research analysts have also recently issued research reports about the company. Citigroup Inc. reaffirmed a buy rating on shares of Eli Lilly and in a research note on Wednesday, August 3rd. Argus raised their target price on Eli Lilly and from $90.00 to $95.00 and gave the stock a buy rating in a research note on Tuesday, August 2nd. BMO Capital Markets reaffirmed a buy rating and set a $94.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 27th. Jefferies Group raised their target price on Eli Lilly and from $100.00 to $105.00 and gave the stock a buy rating in a research note on Thursday, July 14th. Finally, Credit Suisse Group AG reaffirmed a buy rating and set a $91.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 6th. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $97.06.
Shares of Eli Lilly and (NYSE:LLY) opened at 82.09 on Wednesday. Eli Lilly and has a 52 week low of $67.88 and a 52 week high of $88.16. The stock’s 50 day moving average price is $79.44 and its 200-day moving average price is $77.49. The company has a market cap of $86.83 billion, a PE ratio of 35.38 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting the consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the firm posted $0.90 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Analysts expect that Eli Lilly and will post $3.59 EPS for the current year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total value of $16,703,400.00. Following the sale, the insider now directly owns 126,220,804 shares in the company, valued at $10,039,602,750.16. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Donald A. Zakrowski sold 1,213 shares of the business’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the sale, the insider now owns 1,300 shares in the company, valued at $108,108. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of LLY. IFP Advisors Inc boosted its position in shares of Eli Lilly and by 28.2% in the first quarter. IFP Advisors Inc now owns 29,456 shares of the company’s stock valued at $2,121,000 after buying an additional 6,481 shares during the period. Hyman Charles D bought a new position in shares of Eli Lilly and during the first quarter valued at $389,000. MCF Advisors LLC boosted its position in shares of Eli Lilly and by 0.4% in the first quarter. MCF Advisors LLC now owns 3,918 shares of the company’s stock valued at $282,000 after buying an additional 17 shares during the period. CIBC World Markets Inc. boosted its position in shares of Eli Lilly and by 22.3% in the first quarter. CIBC World Markets Inc. now owns 30,487 shares of the company’s stock valued at $2,195,000 after buying an additional 5,563 shares during the period. Finally, Exane Derivatives boosted its position in shares of Eli Lilly and by 164.4% in the first quarter. Exane Derivatives now owns 5,875 shares of the company’s stock valued at $423,000 after buying an additional 3,653 shares during the period. Hedge funds and other institutional investors own 74.96% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.